Literature DB >> 15619616

Synthetic shRNAs as potent RNAi triggers.

Despina Siolas, Cara Lerner, Julja Burchard, Wei Ge, Peter S Linsley, Patrick J Paddison, Gregory J Hannon, Michele A Cleary.   

Abstract

Designing potent silencing triggers is key to the successful application of RNA interference (RNAi) in mammals. Recent studies suggest that the assembly of RNAi effector complexes is coupled to Dicer cleavage. Here we examine whether transfection of optimized Dicer substrates results in an improved RNAi response. Dicer cleavage of chemically synthesized short hairpin RNAs (shRNAs) with 29-base-pair stems and 2-nucleotide 3' overhangs produced predictable homogeneous small RNAs comprising the 22 bases at the 3' end of the stem. Consequently, direct comparisons of synthetic small interfering RNAs and shRNAs that yield the same small RNA became possible. We found synthetic 29-mer shRNAs to be more potent inducers of RNAi than small interfering RNAs. Maximal inhibition of target genes was achieved at lower concentrations and silencing at 24 h was often greater. These studies provide the basis for an improved approach to triggering experimental silencing via the RNAi pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619616     DOI: 10.1038/nbt1052

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  151 in total

Review 1.  Life on a microarray: assessing live cell functions in a microarray format.

Authors:  Krisztián Papp; Zoltán Szittner; József Prechl
Journal:  Cell Mol Life Sci       Date:  2012-03-04       Impact factor: 9.261

2.  RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents.

Authors:  Marta Olejniczak; Paulina Galka-Marciniak; Katarzyna Polak; Andrzej Fligier; Wlodzimierz J Krzyzosiak
Journal:  RNA       Date:  2012-03-12       Impact factor: 4.942

Review 3.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

4.  Reduced seed region-based off-target activity with lentivirus-mediated RNAi.

Authors:  Richard A Klinghoffer; Jill Magnus; Janell Schelter; Michele Mehaffey; Casey Coleman; Michele A Cleary
Journal:  RNA       Date:  2010-03-26       Impact factor: 4.942

5.  Artificial mirtron-mediated gene knockdown: functional DMPK silencing in mammalian cells.

Authors:  Yiqi Seow; Christopher R Sibley; Matthew J A Wood
Journal:  RNA       Date:  2012-05-30       Impact factor: 4.942

6.  A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.

Authors:  Xiaofeng Jiang; Hui Pan; Joseph F Nabhan; Ramaswamy Krishnan; Cynthia Koziol-White; Reynold A Panettieri; Quan Lu
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

7.  Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis.

Authors:  John R Basile; Rogerio M Castilho; Vanessa P Williams; J Silvio Gutkind
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 8.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

9.  Salt intake augments hypotensive effects of transient receptor potential vanilloid 4: functional significance and implication.

Authors:  Feng Gao; Dexin Sui; R Michael Garavito; R Mark Worden; Donna H Wang
Journal:  Hypertension       Date:  2008-12-15       Impact factor: 10.190

10.  A novel role of myosin VI in human prostate cancer.

Authors:  Thomas A Dunn; Shenglin Chen; Dennis A Faith; Jessica L Hicks; Elizabeth A Platz; Yidong Chen; Charles M Ewing; Jurga Sauvageot; William B Isaacs; Angelo M De Marzo; Jun Luo
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.